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Can Novel Biomarkers
Complement Best Possible
Clinical Assessment for Early
Acute Kidney Injury Diagnosis?*
Michael Haase, MD, Anja Haase-Fielitz, PHARMD
agdeburg, Germany
The early diagnosis of acute kidney injury (AKI) appears
now to be within reach, and some already suggest integrat-
ing novel urinary biomarkers in current AKI classification
systems (1,2). Conventional AKI definition relies on mark-
ers of renal function (Risk, Injury, Failure, Loss, and
End-Stage Kidney Disease [RIFLE], Acute Kidney Injury
Network [AKIN]), and diagnosis is therefore often delayed,
perhaps contributing to the unfavorable clinical course of
affected patients. Specifically, serum creatinine requires
several hours to days to accumulate, it increases in serum
only after 50% or more of renal function is lost, and its
concentration is affected by multiple confounding factors.
Urine output, another potential diagnostic biomarker, has
limited sensitivity (3).
See page 2301
Although evidence from numerous studies (4,5) for the
usefulness of novel AKI biomarkers already exists, only a
minority of institutions permanently use biomarkers to
make early AKI diagnosis part of daily clinical routine. Such
incomplete implementation may be explained by some
heterogeneity in the reported predictive ability of biomark-
ers, which is in part related to the use of different AKI
definitions (6) or conditions of sample storage (7). As
another source of heterogeneity, Thurman and Parikh (8)
proposed that the timing of measurement is of importance
for the predictive ability of AKI biomarkers. This aspect of
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Krawczeski et al. (9) in this issue of the Journal.
In this study (9), 4 of the most promising noninvasive
urinary biomarkers (neutrophil gelatinase-associated lipoca-
lin [NGAL], kidney injury molecule [KIM]-1, liver-type
fatty acid-binding protein [L-FABP], and interleukin [IL]-18)
were investigated in a cohort enrolling 220 children without
pre-existing chronic kidney disease and other major comor-
bidities. All patients underwent cardiac surgery with the use
of cardiopulmonary bypass, and all biomarkers were mea-
sured 4 times within 24 h.
The authors found a temporal relationship of the predic-
tive value of these urinary biomarkers and their combina-
tion. Specifically, NGAL was the only biomarker with
predictive value as early as 2 h post-operatively (9), whereas
the other biomarkers had no value at this early time point.
The predictive value of NGAL was very good (area un-
der the curve receiver-operator characteristic [AUC-ROC]
0.9) and independent of the timing of its measurement,
with only minimal improvement over time within the first
24 h. The AUC-ROC values of urinary KIM-1, L-FABP,
and IL-18 slowly progressed and reached good value at 12
to 24 h post-operatively, at a time where, in 98% of patients,
clinical AKI diagnosis was already made. At 6 h and even
more so at 24 h, a combination of renal biomarkers showed
a slightly increased predictive value for AKI as compared
with a single biomarker. Importantly, addition of biomark-
ers resulted in a considerable improvement in early AKI
diagnosis over a clinical model including age and cardiopul-
monary bypass time (net reclassification improvement
[NRI] at 2 h: NGAL 87%, IL-18 14%, L-FABP
17%, and KIM-1 –3%).
The results of this study are novel with regard to the effect
of timing and combination of 4 urinary biomarkers; they are
confirmatory in nature, showing the potential importance of
biomarkers in addition to current AKI diagnosis (10). Just
recently, Parikh et al. (11) also showed, in a multicenter
study, that, when added to clinical risk prediction, urinary
NGAL and IL-18 improved risk classification in pediatric
patients after cardiac surgery. However, compared with
other studies, Krawczeski et al. (9) reported very high NRI
values using no risk categories, as these are currently not
established in the field of AKI. The reported different NRI
values for the same marker added to different models with
different numbers of risk categories should be taken into
consideration when comparing and interpreting findings
across various studies and settings.
Is it worth it to measure a panel of biomarkers, and if so,
which patients might benefit from such measurements? At
this stage, there seems to be no convincing evidence that, in
addition to NGAL, the performance of biomarker panels is
more effective or efficient in early AKI diagnosis.
This study (9) may be criticized because other urinary
biomarkers, such as cystatin C, another promising tubular
biomarker, were not included, and the generalizability of the
a
g
S
u
n
s
m
m
2311JACC Vol. 58, No. 22, 2011 Haase and Haase-Fielitz
November 22, 2011:2310–2 Biomarkers and Acute Kidney Injury Assessmentpresent study is limited due to the fact that only approximately
60% of patients with less severe cardiac and renal disease were
retained for the analysis. In addition, although children are an
ideal type of patient in whom to study AKI biomarkers without
the influence of comorbidities, findings in pediatric studies
have limited transferability to adult patients.
In most biomarker studies—as was done in the present
study (9)—a creatinine-based AKI definition was used.
However, in clinical practice, the evaluation of whether a
patient developed AKI or not is complex. Such evaluation
includes the assessment of changes in urine output and
serum creatinine according to consensus criteria, but also
includes assessment of the slope of creatinine increase and
adjustment for its modification by confounding variables
(e.g., by hemodilution induced by fluid therapy). Further-
more, other aspects of clinical assessment include urine
output in relation to fluid input adjusted for dose of
diuretics, the assessment of hemodynamic variables, and the
sum of other risk factors for AKI (signs of inflammation,
shock, overhydration/dehydration or rhabdomyolysis; met-
abolic acidosis; use, dose, and timing of nephrotoxins;
comorbidities). All these aspects are integrated for the best
possible clinical assessment in making an early AKI diag-
nosis. In the absence of a definitive test for early AKI diagnosis
t the bedside, the more experienced the physician is, the
reater the likelihood for a reasonable diagnostic assessment.
uch experienced clinicians may allocate limited value to the
se of biomarkers, as was initially the case for troponin or brain
atriuretic peptide. Yet, such cardiac biomarkers have been
hown to be superior to clinical assessment in the diagnosis of
yocardial infarction or decompensated heart failure (12). It is
possible, maybe likely, that renal biomarkers will similarly
outperform clinicians in the diagnosis of imminent AKI.
Many types of applications for AKI biomarkers have been
recently tested and found superior to standard clinical
assessment, including their use to predict the need for renal
replacement therapy (13) and recovery from it (14), the
differential diagnosis of serum creatinine increase in patients
admitted to an emergency department (5), the selection
criteria for a subsequent intervention (15), or the ability to
deliver therapeutic monitoring (16). The predictive value of
NGAL for early AKI diagnosis and prognosis has been
summarized in a meta-analysis (4). Finally, measurement of
NGAL in patients at risk of AKI identifies a population
with likely organ injury that cannot be identified by other
tests (1). Such findings suggest that the addition of struc-
tural renal damage markers to AKI consensus definition
needs to be seriously considered.
A proof-of-concept trial randomizing patients to AKI bio-
marker measurement with subsequent classical nephrological
measures is still lacking. However, achieving such demonstra-
tion of therapeutic utility is a complex task, and if achieved, it
would go a step further than any other renal biomarker
(including creatinine, urea, and urine output) has needed to go
in the past.Given the previous considerations, biomarkers with a
clear cut-off may: 1) complement a standardized but still
simple diagnostic approach to AKI; 2) help young clinicians
improve their ability to make an early AKI diagnosis; and
3) perhaps even add to the diagnostic accuracy of experi-
enced physicians. AKI biomarkers have not yet been com-
pared with such a complex endpoint of AKI diagnosis (“best
possible clinical guess”), as described earlier. Beyond com-
plementing physician judgment, the potential advantage of
biomarkers is that they are developed to individually indi-
cate the presence of actual renal damage.
In conclusion, the study by Krawczeski et al. (9) in this
issue of the Journal demonstrates promising biomarkers in
the early diagnosis of AKI in children with congenital heart
disease.
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